In 2022, artificial disc replacement technology has seen significant growth from ongoing research and product developments.
FDA approvals
Centinel Spine in July earned FDA approval for three more Prodisc total disc replacement devices — Prodisc C Vivo, Prodisc C Nova and Prodisc C SK.
Product launches
Jason Tinley, MD, completed the first commercial case with Centinel Spine's Prodisc C Vivo, the devicemaker said in September.
Centinel Spine's Prodisc C SK was used in its first commercial case in November. Ehsan Jazini, MD, performed the debut case.
Milestones
In January, Plano-based Texas Back Institute completed its 3,000th lumbar artificial disc replacement.
France-based Spine Innovations reached a milestone with its lumbar disc replacement device, and it's setting its sights on the U.S. market. The company's ESP disc reached 20,000 cases as of March 28, and it is working toward FDA approval.
Todd Lanman, MD, and Jason Cuellar, MD, PhD, completed the first three-level artificial disc replacement using the Prodisc C Vivo implant in the U.S. The duo operated on a 76-year-old woman with disc degeneration at four levels, the ADR Spinal Restoration Center said Oct. 18. Three levels used the Prodisc C Vivo device, and the fourth level had the original Prodisc C implant.
Research
New York City-based Hospital for Special Surgery and Texas Spine Care Center in San Antonio are part of a multicenter trial examining the effectiveness of three disc replacement devices used for two-level symptomatic cervical disc disease. Researchers are comparing Centinel Spine's Prodisc C SK and Prodisc C Vivo to Zimmer Biomet's Mobi-C cervical disc in the treatment of two-level symptomatic cervical disc disease.